Please assess the completion status of the following clinical trial:

Trial Title: Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis.~* Measurable disease at the time of initial therapy~* Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy.~* Responsive disease to standard chemoradiation therapy as defined by RECIST~* Patients with CR after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation~* CBC with an absolute neutrophil count (ANC) \>/= 1,000/uL, hemoglobin \>/= 8.0 g/DL and platelet count \>/= 75,000/uL.~* Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial.~* Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than 1.5X the upper limit of normal.~* Creatinine clearance of \>/= 60 mL/min~* Pulmonary: DLCO greater than 50%~* Cardiac: left ventricular ejection fraction greater than 45%~Exclusion Criteria:~* Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation~* Pregnant or lactating woman~* HIV infection confirmed by NAT~* Common variable immunodeficiency~* Active CNS malignancy~* Active bacterial, fungal or viral infection~* Unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care~* Prior history of autologous or allogeneic hematopoietic cell transplantation~* Presence of protocol specific comorbid conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adeno virus vectored p53 (Type: EXPERIMENTAL): Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes

Based on this trial design, predict the completion outcome and termination type (if applicable).